The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 92.39 billion by 2030, expanding at a CAGR of 14.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.
Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.
Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.
Request a free sample copy or view report summary: Rare Biomarkers Specimen Collection And Stabilization Market Report
The circulating cell-free DNA (ccfDNA) segment accounted for the largest share of the market at 36.0% in 2024.
The research segment captured the highest share of 74.1% in 2024. The dominance of the rare biomarker segment is largely due to the growing number of research studies focused on their implementation.
The diagnostics segment expected to expand at the CAGR of 15.0% by 2030. While rare biomarkers such as Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and exosomes have primarily been used in research settings, they are increasingly being explored for diagnostic applications.
North America rare biomarkers specimen collection and stabilization industry dominated and accounted for a 52.1% share in 2024.
Grand View Research has segmented the global rare biomarkers specimen collection and stabilization market on the basis of biomarker, end use, and region:
Rare Biomarkers Specimen Collection And Stabilizations Biomarker Outlook (Revenue, USD Million, 2018 - 2030)
Circulating Cell Free DNA (ccfDNA)
Circulating Tumor Cells (CTCs)
Exosomes/Extracellular Vesicles
By Product
Isolation Kits & Reagents
Blood Collection Tubes
Systems
By Specimen Type
Serum/Plasma
Others
By Nucleic Acid & Other Biomolecules
RNA
DNA
Others
By Application
NIPT
Oncology
Research
Diagnostics
Screening
Treatment Monitoring
Transcriptomics
Pharmacogenomics
Transplant Rejection
Population Screening
Cardiovascular Diseases
Other Applications
Circulating Cell Free RNA (ccfRNA) / miRNA
By Product
Isolation Kits & Reagents
Blood Collection Tubes
By Application
NIPT
Oncology
Research
Diagnostics
Transcriptomics
Pharmacogenomics
Transplant Rejection
Population Screening
Cardiovascular Diseases
Other Applications
Rare Biomarkers Specimen Collection And Stabilizations End Use Outlook (Revenue, USD Million, 2018 - 2030)
Research
Research Labs/CROs
Academic Institutes
Diagnostics
Laboratories
Hospitals
Prenatal Clinics
Rare Biomarkers Specimen Collection And Stabilizations Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
Singapore
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Rare Biomarkers Specimen Collection And Stabilizations Market
QIAGEN
Charles River Laboratories
F. Hoffmann-La Roche Ltd
Thermo fischer Scientific Inc.
Eurofins Scientific
PerkinElmer Inc.
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc
Merck KGaA
Siemens Healthcare GmbH
"The quality of research they have done for us has been excellent..."